Michelle E Melisko
Affiliation: University of California
- Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatmentWendy Lorizio
Division of General Internal Medicine, Department of Medicine, University of California San Francisco, 1545 Divisadero Street, Suite 322, San Francisco, CA 94143 0320, USA
Genome Med 3:64. 2011..We evaluated the effect of CYP2D6 testing in clinical practice to determine whether genotype results affected choice of hormone therapy in a prospective cohort study...
- Reactivation of hepatitis C virus after chemotherapy for colon cancerM E Melisko
Comprehensive Cancer Center, University of California, San Francisco, California 94115, USA
Clin Oncol (R Coll Radiol) 16:204-5. 2004..We report the clinical course of HCV reactivation in a patient receiving chemotherapy for metastatic colon cancer. We also review other reports showing the significance of HCV infection in patients being treated with chemotherapy...
- Amelioration of sexual adverse effects in the early breast cancer patientMichelle E Melisko
Department of Medicine, University of California San Francisco, 94115, USA
J Cancer Surviv 4:247-55. 2010....
- Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survivalMichelle E Melisko
Department of Medicine, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
J Neurooncol 88:359-65. 2008..As breast cancer patients live longer with control of systemic disease, survival after the diagnosis of brain metastases (BM) also appears to be improving...
- Brain metastases of breast cancerMichelle E Melisko
Division of Hematology Oncology, University of California at San Francisco, San Francisco, CA 94115, USA
Expert Rev Anticancer Ther 5:253-68. 2005..New approaches include chemotherapy combinations, biologic therapies and novel drug-delivery strategies...
- Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancerJoseph M Letourneau
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California at San Francisco School of Medicine, San Francisco, California, USA
Cancer 118:1933-9. 2012..The authors sought to describe the age-specific impact of infertility and early menopause after chemotherapy among reproductive age women with cancer...
- Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancerA Jo Chien
A Jo Chien, Pamela N Munster, Michelle E Melisko, Hope S Rugo, John W Park, Andrei Goga, Glenna Auerback, Elham Khanafshar, and Mark M Moasser, Helen Diller Family Comprehensive Cancer Center A Jo Chien, Pamela N Munster, Michelle E Melisko, Hope S Rugo, John W Park, Andrei Goga, Glenna Auerback, Elham Khanafshar, Karen Ordovas, and Mark M Moasser, University of California San Francisco, San Francisco, CA and Kevin M Koch, GlaxoSmithKline, Research Triangle Park, NC
J Clin Oncol 32:1472-9. 2014..In mouse models, such doses are not tolerable in continuous administration, but they are tolerable and highly effective in intermittent dosing. We pursued the clinical translation of this treatment hypothesis...
- New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancerMichelle E Melisko
Breast Oncology Clinical Trials Program, UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94115 1710, USA
Nat Clin Pract Oncol 6:25-33. 2009....
- Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriersMichelle E Melisko
University of California, San Francisco, USA
Clin Breast Cancer 6:45-54. 2005..Also, with increasing patient interest in complementary and alternative medicine (CAM) for cancer, we explored attitudes regarding CAM clinical trials...
- A changing perspective: improving access to fertility preservationJoseph M Letourneau
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco School of Medicine, 94143, USA
Nat Rev Clin Oncol 8:56-60. 2011..Finally, we present options for fertility preservation, based on the time point at which consultation occurs...
- Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancerJohn W Park
University of California, San Francisco, San Francisco, CA 94115 1710, USA
J Clin Oncol 25:3680-7. 2007..We conducted a phase I study to evaluate the safety and immunologic activity of lapuleucel-T in patients with HER-2-overexpressing metastatic breast cancer...
- Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancerJoseph M Letourneau
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco School of Medicine, San Francisco, California, USA
Cancer 118:1710-7. 2012..The post-treatment quality of life (QOL) impacts of receiving precancer-treatment infertility counseling and of pursuing fertility preservation have not been described in large-scale studies of reproductive age women with cancer...